Elevation of Plasma Cell-Free Hemoglobin in Pulmonary Arterial Hypertension
Elevation of Plasma Cell-Free Hemoglobin in Pulmonary Arterial Hypertension
复制标题
DOI：
10.1378/chest.14-0809
复制
发表时间：
2014-12-01
期刊：
影响因子：
9.6
通讯作者：
Hemnes, Anna R.
中科院分区：
文献类型：
--
作者：
Brittain, Evan L.;Janz, David R.;Hemnes, Anna R.
背景：无细胞血红蛋白（CFH）是一种有效的一氧化氮清除剂，与几种疾病的不良结局相关。肺动脉高压（PAH）的特征是一氧化氮可用性降低。我们假设，CFH将升高PAH，并将与血流动力学和临床outcome.METHODS：我们测量CFH在200连续评估PAH患者，16个未受影响的骨形态发生受体蛋白2型（BMPR2）突变携带者，19名健康受试者，和29例肺静脉高压（PVH）。结果：PAH和BMPR2携带者的CFH值高于健康人和PVH患者（P
BACKGROUND: Cell-free hemoglobin (CFH) is a potent nitric oxide scavenger associated with poor outcomes in several diseases. Pulmonary arterial hypertension (PAH) is characterized by reduced nitric oxide availability. We hypothesized that CFH would be elevated in PAH and would associate with hemodynamics and clinical outcomes.METHODS: We measured CFH in 200 consecutively evaluated patients with PAH, 16 unaffected bone morphogenetic receptor protein type 2 (BMPR2) mutation carriers, 19 healthy subjects, and 29 patients with pulmonary venous hypertension (PVH). CFH values were tested for association with hemodynamics, time to hospitalization, and death.RESULTS: CFH was elevated in patients with PAH and BMPR2 carriers compared with healthy subjects and patients with PVH (P